Connect® MM- The Multiple Myeloma Disease Registry

Inclusion Criteria:

Cohort 1 and 2

• Newly diagnosed with symptomatic MM within 2 months of enrollment in Connect® MMregistry

• Age ≥18 years

• Willing and able to provide signed informed consent

• Agrees to complete patient assessment questionnaires either alone or with minimalassistance from caregivers and/or trained site personnel

Cohort 3

• Received 1L therapy for symptomatic active MM and subsequently has evidence ofdisease progression. Prior 1L MM treatment received, including anti-myeloma therapy,transplant, chemotherapy, radiation, and surgery, must be known.

• Initiated or intends to initiate 2L systemic therapy for MM after the firstdocumented relapsed/refractory date (i.e. 1L PD).

• Enrollment date must be within 90 days of start date (or intended start date) of 2Lsystemic therapy.

Exclusion Criteria:

Cohort 1 and 2

• None

Cohort 3

• Patient's 1L MM treatment was for smoldering MM or MGUS, and not for symptomatic MM

• Currently active in any MM Registry, including but not limited to, the Connect® MMregistry or another Celgene/BMS-Sponsored registry.

• Patients who have discontinued from Connect® MM or another Celgene/BMS-Sponsoredregistry could be considered for enrollment in Cohort 3, if inclusion and exclusioncriteria are met.

• Currently enrolled or intending to enroll within 90 days in any interventionalclinical trial in which any treatment is an investigational product that cannot beidentified